Related Experiment Video

Updated: Jul 9, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

Management of hyperlipidemia with statins in the older patient

Wilbert S Aronow1

  • 1Department of Medicine, Cardiology and Geriatrics Divisions, New York Medical College, Valhalla, NY 10595, USA. wsaronow@aol.com

Clinical Interventions in Aging
|December 1, 2007
PubMed

Insights

Statins effectively reduce cardiovascular events and mortality in older, high-risk individuals with high cholesterol. Current guidelines recommend specific low-density lipoprotein (LDL) cholesterol targets for various risk levels to improve patient outcomes.

Area of Science:

  • Cardiology
  • Pharmacology
  • Preventive Medicine

Background:

  • Hypercholesterolemia is a significant risk factor for cardiovascular disease.
  • Statins have a well-established role in managing high cholesterol.
  • Evidence supports statin use in older, high-risk populations.

Purpose of the Study:

  • To review the evidence supporting statin use in high-risk individuals.
  • To outline current guidelines for cholesterol management.
  • To discuss lipid-lowering strategies for different patient profiles.

Main Methods:

  • Review of randomized controlled trials and observational studies.
  • Analysis of findings from landmark studies like the Heart Protection Study.
  • Examination of updated National Cholesterol Education Program (NCEP) III guidelines.

Main Results:

  • Statins significantly decrease mortality and major cardiovascular events in high-risk individuals.
  • Benefits are observed irrespective of baseline lipid levels, age, or gender.
  • NCEP III guidelines recommend specific LDL cholesterol targets (<70 mg/dl for very high-risk, <100 mg/dl for moderately high-risk).

Conclusions:

  • Statin therapy is a cornerstone in managing hypercholesterolemia and reducing cardiovascular risk.
  • Personalized lipid-lowering strategies, potentially including combination therapy, are crucial.
  • Adherence to guideline-directed LDL cholesterol targets is essential for optimal patient outcomes.

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism01:18

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism

Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution01:00

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution

Drug distribution in the human body is influenced by several factors, including plasma protein concentration, body composition, blood flow, tissue-protein concentration, and tissue fluid pH. Among these, changes in plasma protein concentration and body composition due to aging significantly affect how drugs are distributed within the body. Specifically, aging is associated with a decrease in albumin levels by about 10% and an increase in α1-acid glycoprotein levels. These alterations are not...
Drug Dosing: Geriatric Patients01:15

Drug Dosing: Geriatric Patients

Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...